When leukemia returns after initial chemotherapy, patients and families face urgent questions about next steps. Advanced therapies including CAR-T cell therapy, stem cell transplant, and clinical trials now offer meaningful options for many relapsed cases. Key Takeaways Early relapse (within 12 months) requires intensive salvage approaches like CAR-T cell therapy or allogeneic stem cell transplant, while late relapse may respond to additional chemotherapy cycles. CAR-T cell t

When leukemia returns after chemotherapy, patients face difficult questions about next steps. Multiple treatment pathways exist, including reinduction chemotherapy, CAR-T cell therapy, allogeneic stem cell transplantation, and clinical trials. Eligibility depends on relapse timing, blast count, CD19 expression, and prior transplant status. Understanding these factors helps patients and families navigate treatment sequencing decisions. Key Takeaways Early relapse (<12 months)